Alpha Cognition Inc. (ACOG)

Alpha Cognition Inc. is a biopharmaceutical company focused on treatments for neurodegenerative diseases. Its lead product, ZUNVEYL (benzgalantamine), is an oral therapy approved in the United States for mild to moderate dementia of the Alzheimer's type. It is designed as a prodrug of galantamine intended to reduce the gastrointestinal side effects that can limit use of existing treatments.

The company commercializes ZUNVEYL in the United States, with an emphasis on long-term care and nursing home settings, and is exploring other uses of its technology, including programs related to cognitive impairment after brain injury. Alpha Cognition is headquartered in Vancouver, British Columbia, and its shares trade on Nasdaq.